Search

Your search keyword '"Terol, M J."' showing total 141 results
Start Over Author "Terol, M J."
141 results on '"Terol, M J."'

1. GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RESPONSES AND A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

Author

Hutchings, M., primary, Avigdor, A., additional, Sureda, A., additional, Terol, M. J., additional, Bosch, F., additional, Corradini, P., additional, Larsen, T. Stauffer, additional, Domínguez, A. Rueda, additional, Skarbnik, A., additional, Jørgensen, J., additional, Goldschmidt, N., additional, Gurion, R., additional, Zinzani, P. L., additional, Pinto, A., additional, Cordoba, R., additional, Bottos, A., additional, Huang, Z., additional, Simko, S., additional, Relf, J., additional, Filézac de L’Etang, A., additional, Sellam, G., additional, and Gritti, G., additional

Published
2023
Full Text
View/download PDF

3. P631: A PCR-BASED ASSAY FOR IGLV3-21R110 SCREENING CONFIRMS ITS PROGNOSTIC VALUE IN AN INDEPENDENT COHORT OF 613 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA.

Author

Syrykh, C., primary, Russiñol, N., additional, Baumann, T., additional, Kulis, M., additional, Alcoceba, M., additional, González, M., additional, Colado, E., additional, Payer, Á. R., additional, Aymerich, M., additional, Terol, M. J., additional, Ruiz-Gaspà, S., additional, López-Guillermo, A., additional, Martín-Subero, J. I., additional, Colomer, D., additional, Delgado, J., additional, Campo, E., additional, and Nadeu, F., additional

Published
2022
Full Text
View/download PDF

4. P1137: ACCURACY AND PROGNOSTIC IMPACT OF FDG PET/CT AND BIOPSY IN BONE MARROW ASSESSMENT OF FOLLICULAR LYMPHOMA AT DIAGNOSIS: A NATION-WIDE STUDY.

Author

Ródenas Quiñonero, I., primary, Chen-Liang, T., additional, Martín-Santos, T., additional, Salar, A., additional, Fernández-González, M., additional, Celades, C., additional, Navarro, J. T., additional, Martinez, A. B., additional, Andreu, R., additional, Balaguer, A., additional, Martín, A., additional, Baile, M., additional, López-Jiménez, J., additional, Marquet, J., additional, Teruel, A. I., additional, Terol, M. J., additional, Benet, C., additional, Frutos, L., additional, Navarro, J. L., additional, Uña, J., additional, Suarez, M., additional, Cortes, M., additional, Contreras, J., additional, Ruiz, C., additional, Tamayo, P., additional, Mucientes, J., additional, Sopena, P., additional, Reguilón-Gallego, L., additional, Sánchez-Blanco, J. J., additional, Pérez-Ceballos, E., additional, Jerez, A., additional, and Ortuño, F. J., additional

Published
2022
Full Text
View/download PDF

5. P1282: DISEASE-SPECIFIC U1 SPLICEOSOMAL RNA MUTATIONS IN MATURE B-CELL NEOPLASMS

Author

Nadeu, F., primary, Shuai, S., additional, Clot, G., additional, Hilton, L. K., additional, Diaz-Navarro, A., additional, Martín, S., additional, Royo, R., additional, Baumann, T., additional, Kulis, M., additional, López-Oreja, I., additional, Cossio, M., additional, Lu, J., additional, Ljungström, V., additional, Young, E., additional, Plevova, K., additional, Knisbacher, B. A., additional, Lin, Z., additional, Hahn, C. K., additional, Bousquets, P., additional, Alcoceba, M., additional, González, M., additional, Colado, E., additional, Aymerich, M., additional, Terol, M. J., additional, Rivas-Delgado, A., additional, Enjuanes, A., additional, Ruiz-Gaspà, S., additional, Chatzikonstantinou, T., additional, Hägerstrand, D., additional, Jylhä, C., additional, Skaftason, A., additional, Mansouri, L., additional, Stranska, K., additional, Doubek, M., additional, van Gastel-Mol, E. J., additional, Davis, Z., additional, Walewska, R., additional, Scarfò, L., additional, Trentin, L., additional, Visentin, A., additional, Parikh, S. A., additional, Rabe, K. G., additional, Moia, R., additional, Armand, M., additional, Rossi, D., additional, Davi, F., additional, Gaidano, G., additional, Kay, N. E., additional, Shanafelt, T., additional, Ghia, P., additional, Oscier, D., additional, Langerak, A. W., additional, Beà, S., additional, López-Guillermo, A., additional, Neuberg, D., additional, Wu, C. J., additional, Getz, G., additional, Pospisilova, S., additional, Stamatopoulos, K., additional, Rosenquist, R., additional, Huber, W., additional, Zenz, T., additional, Colomer, D., additional, Martín-Subero, J. I., additional, Delgado, J., additional, Morin, R. D., additional, Stein, L. D., additional, Puente, X. S., additional, and Campo, E., additional

Published
2022
Full Text
View/download PDF

6. Treatment of High-Risk Acute Lymphoblastic Leukemia. Preliminary Results of the Protocol PETHEMA ALL-93

Author

PETHEMA Cooperative Group. Spanish Society of Hematology, Ribera, J. M., Ortega, J. J., Oriol, A., Fontanillas, M., Maldonado, J., Parody, R., Rivas, C., Hernández-Rivas, J. M., Terol, M. J., Bastida, P., González-Valentín, M. E., Feliu, E., García-Conde, J., Díaz-Mediavilla, J., San Miguel, J. F., Hiddemann, W., editor, Büchner, T., editor, Wörmann, B., editor, Ritter, J., editor, Creutzig, U., editor, Keating, M., editor, and Plunkett, W., editor

Published
1998
Full Text
View/download PDF

7. Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively

Author

Moreno, Carol, Muñoz, C., Terol, M. J., Hernández-Rivas, J. Á., Villanueva, Miguel, and Universitat Autònoma de Barcelona

Subjects
Cancer Research, Chronic lymphocytic leukemia, Tumor burden, Disease, Review, Immune function, Immune Dysfunction, chemistry.chemical_compound, Therapeutic approach, Immune system, Humans, Medicine, Chronic Lymphocytic Leukemia, PI3K/AKT/mTOR pathway, RC254-282, business.industry, Ibrutinib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Oncology, chemistry, Cancer research, Immunotherapy, business, CLL
Abstract

Chronic Lymphocytic Leukemia (CLL) is a hematological malignancy characterized by uncontrolled proliferation of B-cells and severe immune dysfunction. Chemo(immuno)therapies (CIT) have traditionally aimed to reduce tumor burden without fully understanding their effects on the immune system. As a consequence, CIT are usually associated with higher risk of infections, secondary neoplasms and autoimmune disorders. A better understanding of the biology of the disease has led to the development of therapeutic strategies which not only act against malignant B-cells but also reactivate and enhance the patient’s own anti-tumor immune response. Here, we review the current understanding of the underlying interplay between the malignant cells and non-malignant immune cells that may promote tumor survival and proliferation. In addition, we review the available evidence on how different treatment options for CLL including CIT regimens, small molecular inhibitors (i.e, BTK inhibitors, PI3K inhibitors, BCL-2 inhibitors) and T-cell therapies, affect the immune system and their clinical consequences. Finally, we propose that a dual therapeutic approach, acting directly against malignant B-cells and restoring the immune function is clinically relevant and should be considered when developing future strategies to treat patients with CLL.

Published
2021

8. FIVE‐YEAR UPDATE OF THE FIRST‐LINE IMCL‐2015 GELTAMO STUDY. PROLONGED MOLECULAR AND CLINICAL RESPONSES WERE OBSERVED AFTER MRD‐DRIVEN IBRUTINIB DISCONTINUATION.

Author

Giné, E., Medina‐Herrera, A., Cruz, F. de la, Ubieto, A. Jiménez, Jiménez, J. López, García‐ Sancho, A. Martín, Terol, M J., Barca, E. González, Casanova, M., Fuente, A. de la, Niebla, A. Marín, Muntañola, A., López, T. J. González, Aymerich, M., Setoain, X., Cortés‐Romera, M., Rotger, A., Rodríguez, S., López, C., and Nadeu, F.

Subjects
MANTLE cell lymphoma
Abstract

B Conclusions: b An MRD-driven strategy allows ibrutinib discontinuation in indolent clinical forms of MCL patients who persist with prolonged MRD and also clinical responses. At current follow-up, 6 patients remain on treatment, and up to 13 patients discontinued ibrutinib because of adverse events, including 7 associated to ibrutinib with a hemorrhagic cardiac tamponade being the most severe. [Extracted from the article]

Published
2023
Full Text
View/download PDF

9. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

Author

Paiva, B, Vídriales, M-B, Rosiñol, L, Martínez-López, J, Mateos, M-V, Ocio, E M, Montalbán, M-Á, Cordón, L, Gutiérrez, N C, Corchete, L, Oriol, A, Terol, M-J, Echeveste, M-A, De Paz, R, De Arriba, F, Palomera, L, de la Rubia, J, Díaz-Mediavilla, J, Granell, M, Gorosquieta, A, Alegre, A, Orfao, A, Lahuerta, J-J, Bladé, J, and Miguel, J F San

Published
2013
Full Text
View/download PDF

10. THE ROLE OF FDG‐PET/CT AND BONE MARROW BIOPSY IN DETECTING BONE MARROW INVOLVEMENT IN THE INITIAL STAGING OF FOLLICULAR LYMPHOMA: AN ANALYSIS OF ACCURACY AND PROGNOSTIC IMPACT

Author

Reguilón Gallego, L., primary, Chen Liang, T., additional, Martín Santos, T., additional, Salar, A., additional, Fernández González, M., additional, Celades, C., additional, Tomás Navarro, J., additional, Martínez, A.‐B., additional, Andreu, R., additional, Balaguer Rosello, A., additional, Martín, A., additional, Baile, M., additional, López Jiménez, J., additional, Marquet, J., additional, Teruel, A.‐I., additional, Terol, M.‐J., additional, Benet, C., additional, Frutos, L., additional, Navarro, J.‐L., additional, Uña, J., additional, Suarez, M., additional, Cortes, M., additional, Contreras, J., additional, Ruiz, C., additional, Tamayo, P., additional, Mucientes, J., additional, Sopena Novales, P., additional, Sánchez Blanco, J.‐J., additional, Pérez Ceballos, E., additional, Jeréz Cayuela, A., additional, and Ortuño, F., additional

Published
2021
Full Text
View/download PDF

11. EFFICACY AND SAFETY OF IBRUTINIB IN COMBINATION WITH RITUXIMAB AS FRONTLINE TREATMENT FOR INDOLENT CLINICAL FORMS OF MANTLE CELL LYMPHOMA. RESULTS OF THE GELTAMO IMCL‐2015 STUDY

Author

Giné, E., primary, De la Cruz, F., additional, Ubieto, A. Jiménez, additional, Jiménez, J. López, additional, García‐Sancho, A. Martín, additional, Terol, M. J., additional, González‐Barca, E., additional, Casanova, M., additional, De la Fuente Burguera, A., additional, Niebla, A. Marín, additional, Prat, A. Muntanola, additional, González‐López, T. J., additional, Aymerich, M., additional, Setoain, X., additional, Cortés‐Romera, M., additional, Rotger, A., additional, Medina, A., additional, García‐Sanz, R., additional, Campo, E., additional, and López‐Guillermo, A., additional

Published
2021
Full Text
View/download PDF

12. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

Author

Paiva, B, Gutiérrez, N-C, Chen, X, Vídriales, M-B, Montalbán, M-Á, Rosiñol, L, Oriol, A, Martínez-López, J, Mateos, M-V, López-Corral, L, Díaz-Rodríguez, E, Pérez, J-J, Fernández-Redondo, E, de Arriba, F, Palomera, L, Bengoechea, E, Terol, M-J, de Paz, R, Martin, A, Hernández, J, Orfao, A, Lahuerta, J-J, Bladé, J, Pandiella, A, and Miguel, J-F San

Published
2012
Full Text
View/download PDF

13. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma

Author

Paiva, B, Pérez-Andrés, M, Vídriales, M-B, Almeida, J, de las Heras, N, Mateos, M-V, López-Corral, L, Gutiérrez, N C, Blanco, J, Oriol, A, Hernández, M T, de Arriba, F, de Coca, A G, Terol, M-J, de la Rubia, J, González, Y, Martín, A, Sureda, A, Schmidt-Hieber, M, Schmitz, A, Johnsen, H E, Lahuerta, J-J, Bladé, J, San-Miguel, J F, and Orfao, A

Published
2011
Full Text
View/download PDF

19. High-dose therapy/autologous stem cell transplantation increases complete remission rate in multiple myeloma irrespective of the induction regimen used: TD (Thalidomide/dexamethasone), VTD (bortezomib/thalidomide/dexamethasone) or VBMCP/VBAD plus bortezom: O162

Author

Rosiñol, L., Cibeira, M. T., Martínez, J., Mateos, M. V., Terol, M. J., de la Rubia, J., Palomera, L., de Arriba, F., Oriol, A., Alegre, A., Besalduch, J., de Paz, R., García-Laraña, J., Díaz-Mediavilla, J., Sureda, A., Lahuerta, J. J., San Miguel, J., and Bladé, J.

Published
2009

24. Autologous stem cell transplantation for primary refractory Hodgkinʼs disease: results and clinical variables affecting outcome

Author

Constans, M., Sureda, A., Terol, M. J., Arranz, R., Caballero, M. D., Iriondo, A., Jarque, I., Carreras, E., Moraleda, J. M., Carrera, D., León, A., López, A., Albó, C., Díaz-Mediavilla, J., Fernández-Abellán, P., García-Ruiz, J. C., Hernández-Navarro, F., Mataix, R., Petit, J., Pascual, M. J., Rifón, J., García-Conde, J., Fernández-Rañada, J. M., Mateos, M. V., Sierra, J., and Conde, E.

Published
2003

28. Erratum: A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

Author

Paiva, B, Vídriales, M-B, Rosiñol, L, Martínez-López, J, Mateos, M-V, Ocio, E M, Montalbán, M-Á, Cordón, L, Gutiérrez, N C, Corchete, L, Oriol, A, Terol, M-J, Echeveste, M-A, De Paz, R, De Arriba, F, Palomera, L, de la Rubia, J, Díaz-Mediavilla, J, Granell, M, Gorosquieta, A, Alegre, A, Orfao, A, Lahuerta, J-J, Bladé, J, and San Miguel, J F

Published
2013
Full Text
View/download PDF

29. Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia

Author

Nadeu, F, primary, Clot, G, additional, Delgado, J, additional, Martín-García, D, additional, Baumann, T, additional, Salaverria, I, additional, Beà, S, additional, Pinyol, M, additional, Jares, P, additional, Navarro, A, additional, Suárez-Cisneros, H, additional, Aymerich, M, additional, Rozman, M, additional, Villamor, N, additional, Colomer, D, additional, González, M, additional, Alcoceba, M, additional, Terol, M J, additional, Navarro, B, additional, Colado, E, additional, Payer, ÁR, additional, Puente, X S, additional, López-Otín, C, additional, López-Guillermo, A, additional, Enjuanes, A, additional, and Campo, E, additional

Published
2017
Full Text
View/download PDF

30. Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia

Author

Nadeu, F, Clot, G, Delgado, J, Martín-García, D, Baumann, T, Salaverria, I, Beà, S, Pinyol, M, Jares, P, Navarro, A, Suárez-Cisneros, H, Aymerich, M, Rozman, M, Villamor, N, Colomer, D, González, M, Alcoceba, M, Terol, M J, Navarro, B, Colado, E, Payer, ÁR, Puente, X S, López-Otín, C, López-Guillermo, A, Enjuanes, A, and Campo, E

Abstract

Genome studies of chronic lymphocytic leukemia (CLL) have revealed the remarkable subclonal heterogeneity of the tumors, but the clinical implications of this phenomenon are not well known. We assessed the mutational status of 28 CLL driver genes by deep-targeted next-generation sequencing and copy number alterations (CNA) in 406 previously untreated patients and 48 sequential samples. We detected small subclonal mutations (0.6–25% of cells) in nearly all genes (26/28), and they were the sole alteration in 22% of the mutated cases. CNA tended to be acquired early in the evolution of the disease and remained stable, whereas the mutational heterogeneity increased in a subset of tumors. The prognostic impact of different genes was related to the size of the mutated clone. Combining mutations and CNA, we observed that the accumulation of driver alterations (mutational complexity) gradually shortened the time to first treatment independently of the clonal architecture, IGHV status and Binet stage. Conversely, the overall survival was associated with the increasing subclonal diversity of the tumors but it was related to the age of patients, IGHV and TP53 status of the tumors. In conclusion, our study reveals that both the mutational complexity and subclonal diversity influence the evolution of CLL.

Published
2018
Full Text
View/download PDF

31. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group

Author

Sanz, M. A., Martín, G., Rayón, C., Esteve, J., González, M., Díaz-Mediavilla, J., Bolufer, P., Barragán, E., Terol, M. J., González, J. D., Colomer, D., Chillón, C., Rivas, C., Gómez, T., Ribera, J. M., Bornstein, R., Román, J., Calasanz, M. J., Arias, J., Alvarez, C., Ramos, F., and Debén, G.

Subjects
Adult, Male, Adolescent, Oncogene Proteins, Fusion, Tretinoin, Middle Aged, Neoplasm Proteins, Treatment Outcome, Leukemia, Promyelocytic, Acute, Antineoplastic Combined Chemotherapy Protocols, Humans, Anthracyclines, Female, Idarubicin, Aged
Abstract

The Spanish PETHEMA group designed a protocol for newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia (APL) in which induction and consolidation followed the original AIDA regimen, except for the omission of cytarabine and etoposide from consolidation. Induction consisted of 45 mg/m(2) all-trans retinoic acid (ATRA) daily until complete remission (CR) and 12 mg/m(2) idarubicin on days 2, 4, 6, and 8. Patients in CR received 3 monthly chemotherapy courses: idarubicin 5 mg/m(2)/d x 4 (course no. 1), mitoxantrone 10 mg/m(2)/d x 5 (course no. 2), and idarubicin 12 mg/m(2)/d x 1 (course no. 3). Maintenance therapy consisted of 90 mg/m(2)/d mercaptopurine orally, 15 mg/m(2)/wk methotrexate intramuscularly, and, intermittently, 45 mg/m(2)/d ATRA for 15 days every 3 months. Between November 1996 and December 1998, 123 patients with newly diagnosed PML/RARalpha-positive APL from 39 centers were enrolled. A total of 109 patients achieved CR (89%; 95% confidence interval [CI], 83 to 95), 12 died of early complications, and the remaining 2 were resistant. Consolidation treatment was associated with very low toxicity and no deaths in remission were recorded. Molecular assessment of response by reverse transcriptase-polymerase chain reaction (RT-PCR) showed conversion to PCR-negative in 48 of 99 (51%) and 82 of 88 patients (93%) after induction and consolidation, respectively. The 2-year Kaplan-Meier estimates of overall survival and event-free survival were 82% +/- 4% and 79% +/- 4%, respectively. For patients who achieved CR, the 2-year disease-free survival (DFS) was 92% +/- 3%. These data indicate that a significant reduction in toxicity might be obtained in APL using a less intensive consolidation without apparently compromising the antileukemic effect. These results also suggest a minor role for cytarabine and etoposide in the treatment of newly diagnosed PML/RARalpha-positive APL patients.

Published
1999

32. Acadesine for Patients With Relapsed/refractory Chronic Lymphocytic Leukemia: a Multicentre Phase I/ii Study

Author

UCL - Cliniques universitaires Saint-Luc, UCL - SSS/DDUV - Institut de Duve, Van Den Neste, Eric, Janssens, A., Gonzalez-Barca, E., Cazin, B., Terol, M. J., Levy, V., Perez de Oteyza, J., Saunders, A., De Elias, M., Campas, C., 15th Annual Meeting of the European-Hematology-Association, UCL - Cliniques universitaires Saint-Luc, UCL - SSS/DDUV - Institut de Duve, Van Den Neste, Eric, Janssens, A., Gonzalez-Barca, E., Cazin, B., Terol, M. J., Levy, V., Perez de Oteyza, J., Saunders, A., De Elias, M., Campas, C., and 15th Annual Meeting of the European-Hematology-Association

Published
2010

33. First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group

Author

Arranz, R., primary, Garcia-Noblejas, A., additional, Grande, C., additional, Cannata-Ortiz, J., additional, Sanchez, J. J., additional, Garcia-Marco, J.-A., additional, Alaez, C., additional, Perez-Calvo, J., additional, Martinez-Sanchez, P., additional, Sanchez-Gonzalez, B., additional, Canales, M.-A., additional, Conde, E., additional, Martin, A., additional, Arranz, E., additional, Terol, M.-J., additional, Salar, A., additional, and Caballero, D., additional

Published
2013
Full Text
View/download PDF

34. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression

Author

Mateos, M.-V., primary, Hernandez, J. M., additional, Hernandez, M. T., additional, Gutierrez, N. C., additional, Palomera, L., additional, Fuertes, M., additional, Garcia-Sanchez, P., additional, Lahuerta, J. J., additional, de la Rubia, J., additional, Terol, M.-J., additional, Sureda, A., additional, Bargay, J., additional, Ribas, P., additional, Alegre, A., additional, de Arriba, F., additional, Oriol, A., additional, Carrera, D., additional, Garcia-Larana, J., additional, Garcia-Sanz, R., additional, Blade, J., additional, Prosper, F., additional, Mateo, G., additional, Esseltine, D.-L., additional, van de Velde, H., additional, and San Miguel, J. F., additional

Published
2008
Full Text
View/download PDF

35. Re-Treatment with Rituximab Plus Chemotherapy in Patients with Diffuse Large-B Cell Lymphoma (DLBCL): A Spanish Multicenter Study.

Author

Canales, Miguel A., primary, Palacios, A., primary, Martinez-Chamorro, C., primary, Cruz, M. A., primary, Moraleda, J. M., primary, Terol, M. J., primary, Almagro, M., primary, Garcia-Vela, J. A., primary, Aguiar, D., primary, Caballero, D., primary, Sancho, J. M., primary, Ferrer, S., primary, Rueda, A., primary, Calvo, J. M., primary, Fernandez, J. A., primary, Diaz-Mediavilla, J., primary, Gonzalez, J., primary, Mayans, J., primary, Montesinos, C., primary, Rios, E., primary, Ruedas, A., primary, Sabin, P., primary, and Fernandez-Jurado, A., primary

Published
2005
Full Text
View/download PDF

41. Low-Grade Lymphoma: Clinical and Prognostic Studies in a Series of 143 Patients from a Single Institution

Author

Lopez-Guillermo, A., primary, Montserrat, E., additional, Bosch, F., additional, Escoda, L., additional, Terol, M. J., additional, Marin, P., additional, Reverter, J. C., additional, Blade, J., additional, Cervantes, F., additional, Sierra, J., additional, Nomdedeu, B., additional, Urbano-Ispizua, A., additional, Rouira, M., additional, Carreras, E., additional, Campo, E., additional, and Rozman, C., additional

Published
1994
Full Text
View/download PDF

44. Long-term follow-up analysis on the prognostic influence of antigenic markers in multiple myeloma: A study on 712 patients uniformly treated with high-dose therapy

Author

Mateo, G., Mateos, M. V., Montalban, M. A., Vidriales, M. B., Rosinol, L., Montejano, L., Lopez-Berges, C., Blade, J., Lahuerta, J. J., Martinez, R., La Rubia, J., Diaz-Mediavilla, J., Sureda, A., Jose-Maria Ribera, Ojanguren, J. M., Arriba, F., Palomera, L., Terol, M. J., Gardella, S., Fernandez-Calvo, E. J., Orfao, A., and Miguel, J. F. San

48. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial

Author

Jose-Maria Ribera, Oriol, Albert, Bethencourt, Concepcion, Parody, Ricardo, Hernandez-Rivas, Jesus-Maria, Moreno, Maria-Jose, Del Potro, Eloy, Tormo, Mar, Rivas, Concepcion, Besalduch, Joan, Sanz, Miguel-Angel, Ortega, Juan-Jose, Feliu, E., Queipo Llano, M. J., Fernandez-Abellan, P., Terol, M. J., Besalduch, J., Novo, A., Moscardo, F., Arias, J., Moraleda, J. M., Heras, I., Bueno, J., Fernandez-Calvo, J., Borrego, D., Martin-Reina, V., Deben, G., Carbonell, F., Orts, M., Vivancos, P., Grande, C., Bello, Jl, Queizan, J. A., Guinea, J., Brunet, S., Bergua, J. L., Rodriguez-Villa, A., Atutxa, K., Diaz-Morfa, G., Hernandez-Nieto, L., Gamez, F., Llorente, A., Ortega-Rivas, F., Penarrubia, M. D., Poderos, C., Marti, J. M., and Gardella, S.

Catalog

Books, media, physical & digital resources
See catalog results